ArticleAmerican journal of clinical dermatology2024

Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

Brett King et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.